[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertensive-disorder-of-pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertensive-disorder-of-pregnancy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,49,84,109,133,164,187,222,242,267,290,314,339,362,384,414],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100611692","mobile-based-obstetric-monitoring-for-pregnancies-complicated-by-hypertension-andor-diabetes-mom-hd-100611692",false,"NCT07243886","Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and\u002For Diabetes (MOM-HD)","Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and\u002For Diabetes (MOM-HD): a Type II Hybrid Implementation-Effectiveness Trial","MOM-HD","Inclusion Criteria:\n\n* Pregnant women receiving antenatal care at RCT site\n* Diagnosed with one of the following:\n\n  * Chronic hypertension (sustained systolic BP ≥140 mm Hg and\u002For diastolic BP ≥90 mm Hg, or on antihypertensive treatment before 20 weeks of gestation)\n  * Gestational hypertension or preeclampsia without severe features (sustained systolic BP ≥140 mm Hg and\u002For diastolic BP ≥90 mm Hg after 20 weeks of gestation)\n  * Gestational diabetes\n* Age 18 years or older\n* Access to a smartphone\n* Gestational age ≤ 34 weeks at enrollment\n\nExclusion Criteria:\n\n* Multifetal pregnancies\n* Apparent communication difficulties (e.g., hearing, speech, or cognitive impairments), as judged by research assistants\n* Unable to understand the Nepali language\n* Severe maternal illness or any condition that precludes active study participation (e.g., preeclampsia with severe features, eclampsia, HELLP syndrome, or other conditions requiring inpatient management)\n* Declines to provide informed consent","FEMALE","18 Years",{"count":20,"type":21},864,"ESTIMATED","INTERVENTIONAL",[24],"NA","Hypertensive disorders during pregnancy (HDP) and gestational diabetes (GDM) are among the leading complications in pregnancy, significantly contributing to global maternal and fetal morbidity and mortality. (1,2,3) Effective management of HDP and GDM hinges on regular monitoring of blood pressure (BP) and blood glucose (BG) to ensure adequate control and timely interventions for maternal and fetal well-being. Telemonitoring offers a promising and cost-effective alternative by enabling pregnant individuals to monitor BP and BG at home and share real-time results with healthcare providers, facilitating informed clinical decision-making and timely interventions.\n\nHere the investigators propose to conduct a Hybrid Type II Effectiveness-Implementation Randomized Controlled Trial (RCT) to assess the effectiveness and evaluate the implementation of the MOM-HD (Mobile-based Obstetric Monitoring for Hypertension and\u002For Diabetes) program, a mobile app-based perinatal telemonitoring program, in real-world clinical settings in Nepal. To address the study aims, the investigators will recruit 864 women who are newly diagnosed with HDP and GDM from three metropolitan hospitals and randomly assign them to either (i) MOM-HD + standard care or (ii) standard care alone, from enrolment in pregnancy to 6 weeks postpartum. Primary and secondary clinical outcomes will be assessed at delivery, and at 6 weeks postpartum. The investigators hypothesize that compared to standard care, the use of MOM-HD in addition to standard care will result in lower systolic BP levels, lower incidence rate for the composite adverse perinatal outcome of either perinatal loss, neonatal intensive care unit admission, primary cesarean delivery or labor induction, and lower proportion of days with elevated systolic BP or BG readings between recruitment and 6 weeks postpartum. A convergent mixed-methods approach will be used to assess implementation and maintenance outcomes using the RE-AIM framework (4), and economic sustainability will be assessed by collecting primary cost data.",[27,28],"Gestational Diabetes","Hypertensive Disorder of Pregnancy",[30,31,32,33,34,35,36],"pregnancy","telemonitoring","mHealth","GDM","HDP","Nepal","implementation","NOT_YET_RECRUITING","2026-06-03",{"date":40,"type":41},"2026-06-05","ACTUAL",{"date":43,"type":21},"2026-09-01",{"date":45,"type":21},"2030-12-31",{"name":47,"class":48},"Rutgers, The State University of New Jersey","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":73,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100537733","phase-4-treatment-with-aspirin-after-preeclampsia-tap-trial-100537733","NCT06281665","Treatment With Aspirin After Preeclampsia: TAP Trial","TAP","Inclusion Criteria:\n\n* Postpartum individuals ≥18 years old\n* Preeclampsia diagnosis\n\nExclusion Criteria:\n\n* Fetal anomaly\n* Multiple gestation\n* Pre-pregnancy hypertension\n* Allergy or contraindication to low-dose aspirin\n* Pre-pregnancy diabetes","55 Years",{"count":58,"type":21},60,[60],"PHASE4","The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and\u002For microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.",[28,63,64,65,66,67,68,69,70,71,72],"Pre-Eclampsia","Hypertension","Eclampsia","Gestational Hypertension","Cardiovascular Diseases","Toxemia","Pregnancy Complications","Vascular Diseases","Hypertension, Pregnancy Induced","Hypertension;Pre-Eclamptic",[64],"RECRUITING",{"date":76,"type":41},"2026-06-04",{"date":78,"type":41},"2024-05-29",{"date":80,"type":21},"2027-09-01",{"name":82,"class":48},"Malamo Countouris",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100627435","phase-4-progesterone-preeclampsia-100627435","NCT07448597","Progesterone Preeclampsia","Progesterone Supplementation for the Prevention of Preeclampsia","Inclusion Criteria:\n\n* Pregnant individuals receiving prenatal care at participating clinics\n* \\\u003C12 weeks gestation with a viable intrauterine pregnancy\n* Age ≥18 years\n* English-speaking\n\nExclusion Criteria:\n\n* Unable or unwilling to self-administer vaginal progesterone\n* Inability or unwillingness to provide informed consent",true,{"count":93,"type":21},642,[60],"This randomized controlled trial evaluates whether nightly vaginal micronized progesterone (400 mg) initiated before 12 weeks' gestation reduces the incidence of preeclampsia in low-risk pregnant individuals. Participants will be randomly assigned (1:1) to receive either vaginal progesterone through 16 weeks' gestation or routine prenatal care without progesterone. Maternal and neonatal outcomes-including development of preeclampsia, obstetric complications, gestational diabetes, preterm birth, and neonatal morbidity-will be collected via chart review. The study aims to determine whether early progesterone supplementation decreases the risk of preeclampsia.",[97,28],"Preeclampsia",[99],"Progesterone","2026-05-27",{"date":102,"type":41},"2026-05-29",{"date":104,"type":21},"2026-08-01",{"date":106,"type":21},"2028-05-01",{"name":108,"class":48},"Medical University of South Carolina",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":91,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100616946","a-prospective-longitudinal-observational-cohort-study-of-pregnant-women-residing-at-high-altitude-in-bolivia-100616946","NCT07312227","A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia","Inclusion Criteria:\n\n* women delivering at participating hospitals at more than 3500 meters or women delivering at participating hospitals at sea level\n* signed informed consent\n\nExclusion Criteria:\n\n* preexisting cardiopulmonary pathologies (CHD, COPD, CKD, NYHA \\> III)","45 Years",{"count":117,"type":21},27,"OBSERVATIONAL","In this study, the investigators will follow two small cohorts of pregnant women: a cohort of healthy women with uncomplicated pregnancies residing at high altitude, a control group of healthy women with uncomplicated pregnancies residing at sea level, to characterize differences in cardiopulmonary adaptation and nitric oxide (NO) pathway expression at elevations \\>3,500 m throughout pregnancy and into the postpartum period. The investigators aim to investigate right-sided cardiac impairment induced by chronic hypobaric hypoxemia, its effects on fetal growth, and the potential contribution of cardiovascular nitric oxide depletion to obstetric complications.",[28,121,122],"Pulmonary Arterial Hypertension","Intrauterine Growth Restriction","2026-05-21",{"date":125,"type":41},"2026-05-26",{"date":127,"type":41},"2026-02-11",{"date":129,"type":21},"2027-02",{"name":131,"class":48},"Massachusetts General Hospital",2,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":91,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":147,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":83},"100624137","arm-position-and-blood-pressure-measurement-accuracy-during-pregnancy-100624137","NCT07405723","Arm Position and Blood Pressure Measurement Accuracy During Pregnancy","Arm Position and Blood Pressure Measurement Accuracy in Pregnancy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Pregnant women aged 18 to 55 years\n* Singleton or multiple viable intrauterine pregnancy\n* Gestational age corresponding to first, second, or third trimester at the time of enrollment\n* Ability to sit upright comfortably for the duration of blood pressure measurements\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Preexisting significant cardiac disease (e.g., arrhythmias, congenital heart disease, severe valvular disease)\n* Chronic kidney disease defined as serum creatinine ≥1.5 mg\u002FdL at enrollment\n* Significant upper limb or shoulder conditions that may affect arm positioning or blood pressure measurement (e.g., lymphedema, fractures, prior surgery, arteriovenous fistula)\n* Neurological or musculoskeletal conditions preventing proper positioning\n* Severe preeclampsia, eclampsia, or other acute medical conditions requiring immediate intervention\n* Major fetal anomaly\n* Intrauterine fetal demise",{"count":141,"type":21},300,[24],"Accurate blood pressure measurement is essential during pregnancy, as blood pressure readings guide clinical decisions related to the diagnosis and management of hypertensive disorders of pregnancy. Clinical guidelines recommend measuring blood pressure with the arm supported at heart level; however, in routine practice, blood pressure is often measured with the arm in non-standard positions.\n\nThis study aims to evaluate how different arm positions affect blood pressure measurements in pregnant women. Pregnant women attending a high-risk pregnancy clinic will undergo blood pressure measurements with the arm placed in several commonly used positions, including supported at heart level, supported on the lap, and unsupported at the side. Each participant will have multiple measurements taken during a single clinic visit.\n\nThe study is designed as a randomized crossover trial with stratification by trimester and chronic hypertension status, allowing each participant to serve as her own control. Participants will be enrolled across all three trimesters of pregnancy, and results will be analyzed separately for each trimester. The primary outcome is the difference in systolic and diastolic blood pressure measurements between arm positions.\n\nThe findings of this study may help improve the accuracy of blood pressure measurement during pregnancy and inform clinical practice regarding optimal measurement techniques.",[145,146,28],"Pregnancy","Blood Pressure Measurement in Pregnancy",[148,145,149,150,151,152,153],"Blood Pressure Measurement","Arm Position","Hypertensive Disorders of Pregnancy","Prenatal Care","Blood Pressure Accuracy","Randomized Crossover Trial","2026-04-13",{"date":156,"type":41},"2026-04-16",{"date":158,"type":41},"2026-04-12",{"date":160,"type":21},"2026-12-31",{"name":162,"class":163},"Sheba Medical Center","OTHER_GOV",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":186},"100582134","improving-maternal-cardiovascular-outcomes-through-the-implementation-of-a-hypertensive-disorders-of-pregnancy-bundle-in-nigeria-100582134","NCT06859359","Improving Maternal Cardiovascular Outcomes Through the Implementation of a Hypertensive Disorders of Pregnancy Bundle in Nigeria","IMPACT-HDP","Inclusion Criteria:\n\n* Postpartum adults (\\>18 years)\n* postpartum emancipated minors (in accordance with the Nigerian guidelines for young persons' participation in research and reproductive health services)\n* with diagnosis of HDP prior to delivery delivered at one of the participating sites able to provide informed consent.\n\nExclusion Criteria:\n\n* unable to provide consent.",{"count":172,"type":21},1200,[24],"The goal of this interventional study is to learn from patients and healthcare providers at 4 health institutions (study sites) in Abuja and Kano in Nigeria what ways to best develop the content of a Hypertensive Disorders of Pregnancy ( HDP) Management package for pregnant women, and evaluate the effectiveness of implementing this package in improving cardiovascular health of pregnant women. The main question it aims to answer is:\n\nWill a contextualized home BP monitoring program lead to better BP control among patients with HDP in Nigeria?",[28],[64,145,97,34],"2026-03-25",{"date":179,"type":41},"2026-03-30",{"date":181,"type":41},"2024-08-08",{"date":183,"type":21},"2029-06",{"name":185,"class":48},"Washington University School of Medicine",4,{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":91,"sex":17,"minAge":18,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":198,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":83},"100516079","multiparametric-assessment-of-maternal-vascular-function-in-the-prediction-of-hypertensive-disorders-of-pregnancy-100516079","NCT05999851","Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy","Multiparametric Assessment of Maternal Vascular Function as a New Diagnostic and Prognostic Tool for Hypertensive Disorders of Pregnancy and Preeclampsia - EDIPE Study","EDIPE","Inclusion Criteria:\n\n* Age greater than or equal to 18 years\n* Single pregnancy\n* No previous pregnancies lasting more than 12 weeks\n* Participant willing and able to give informed consent for participation in the study\n\nExclusion Criteria:\n\n* Intermediate-high risk of genetic abnormalities and\u002For need to perform invasive tests (amniocentesis, villocentesis)\n* History of solid organ or hematopoietic stem cell transplantation\n* Chronic renal failure (eGFR≤45ml\u002Fmin\u002F1.73m2)\n* Chronic treatment with antihypertensive drugs and\u002For xanthine oxidase (XO) inhibitors","65 Years",{"count":197,"type":21},400,[24],"The present study is a single-centre prospective study that will enrol pregnant women during their first trimester of pregnancy (11+0 - 13+6 weeks of gestation).\n\nDuring pregnancy, women will undergo standard clinical evaluation and management. During the two study visits (enrollment and 24+0 - 27+6 weeks of gestation) the investigators will perform arterial tonometry (Pulsepen) and in vivo darkfield microscopy (Glycocheck) to evaluate endothelial and vascular function. A urine sample and a blood sample for specific study analyses on metabolic profile, endothelial and angiogenic markers will be collected. Pregnancy outcomes will be collected at delivery and five years after delivery all the participants will be interview to collect long-term cardiovascular outcomes. Serum endothelial and angiogenic markers will be evaluated only in participants who will develop hypertensive disorders of pregnancy and in an equal number of controls matched for age and body mass index at the time of conception.",[97,28],[97,150,64,202,203,204,205,206,207,208,209,210,211,212],"Obstetric Medicine","Cardio-Obstetrics","Cardiovascular outcomes","Pregnancy complications","Arterial Stiffness","Endothelial Glycocalyx","Endothelial dysfunction","Uric Acid","Oxidative stress","Xanthine oxidase","Lipids","2026-01-21",{"date":215,"type":41},"2026-01-22",{"date":217,"type":41},"2023-09-01",{"date":219,"type":21},"2031-09",{"name":221,"class":48},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":83},"100608684","hope-bp-20-evaluating-the-optimal-duration-of-postpartum-remote-blood-pressure-monitoring-100608684","NCT07204756","HOPE-BP 2.0: Evaluating the Optimal Duration of Postpartum Remote Blood Pressure Monitoring","Inclusion Criteria:\n\n* 18 years or older\n* Discharged after delivery at University of Minnesota Medical Center\n* Enrolled into the HOPE-BP Program\n\nExclusion Criteria:\n\n* Ongoing antihypertensive medication use at 2 weeks (time of randomization)\n* Have a medical comorbidity that would not be clinically appropriate to randomize\n* Patients opted out of clinical research",{"count":197,"type":21},[24],"Postpartum remote blood pressure monitoring programs for patients with hypertensive disorders of pregnancy (HDP) are becoming part of standard postpartum management. Existing programs range in duration from 2 to 6 weeks but there has not been any evaluation as to what program duration is optimal. The primary objective of this study is to evaluate the impact of program duration on clinical outcomes for patients participating in a single institution's postpartum remote blood pressure monitoring program for patients with HDP.",[232,64,28],"Postpartum","2026-01-12",{"date":235,"type":41},"2026-01-14",{"date":237,"type":41},"2026-01-07",{"date":239,"type":21},"2028-01-31",{"name":241,"class":48},"University of Minnesota",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":4},"100615989","evaluation-of-patients-with-hypertensive-disorders-of-pregnancy-an-ambispective-observational-study-100615989","NCT07299773","Evaluation of Patients With Hypertensive Disorders of Pregnancy: An Ambispective Observational Study","PREP","Inclusion Criteria:\n\n* Pregnancies complicated by preeclampsia or gestational hypertension ≥22 weeks\n* Age ≥18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* intrauterine fetal demise\n* Major fetal anomalies or chromosomal abnormalities\n* Maternal cardiac disease or ongoing cardiologic therapy\n* Chronic kidney disease\n* Twin or multiple pregnancies\n* Pregestational diabetes",{"count":250,"type":21},120,"The overall objective of this study is to evaluate the prognostic role of ultrasound and laboratory parameters, specifically their potential ability to predict severe forms of preeclampsia and adverse maternal-fetal outcomes.\n\nIn particular, the aim of the present research is to obtain data on the prognostic value of ultrasonographic and biochemical parameters in patients with hypertensive disorders of pregnancy.",[97,253,28],"Preeclampsia (PE)",[255,256,257],"preeclampsia","ophtalmic nerve","ophtalmic artery","2025-12-17",{"date":260,"type":41},"2025-12-23",{"date":262,"type":21},"2026-01-01",{"date":264,"type":21},"2027-12-01",{"name":266,"class":48},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":17,"minAge":274,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":22,"phases":278,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":132},"100491234","the-achieve-trial-achieving-longer-gestation-in-preeclampsia-via-antihypertensive-therapy-100491234","NCT05676476","The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.","Achieve","Inclusion Criteria:\n\n* Pregnant women\n* Gestational age: 23 weeks, 0 days to 35 weeks, 6 days\n* Hypertensive disorder of pregnancy including gestational hypertension or preeclampsia, the non-severe form at enrollment, which is called without severe features by the American College of Obstetricians and Gynecologists.\n* No evidence of the severe form of preeclampsia, termed severe features, as outlined in maternal exclusions\n* No indication for delivery at the time of enrollment.\n* Planned expectant management at time of enrollment\n* Singleton or dichorionic twin gestation, defined at and beyond 14 weeks gestation. (A pregnancy complicated by a vanishing twin in the first trimester defined as less than 14 weeks gestation will be eligible.)\n* Intact membranes\n\nExclusion Criteria:\n\n* Preeclampsia with severe features, defined per ACOG as:\n* Systolic blood pressure of 160 mm Hg or more, or diastolic blood pressure of 110 mm Hg or more on two occasions at least 4 hours apart (unless antihypertensive therapy is initiated before this time)\n* Thrombocytopenia defined as: lower than 100 x 10e9 platelets\u002FL\n* Impaired liver function that is not accounted for by alternative diagnoses and as indicated by abnormally elevated blood concentrations of liver enzymes (to more than twice the upper limit normal concentrations), or by severe persistent right upper quadrant or epigastric pain unresponsive to medications\n* Renal insufficiency (serum creatinine concentration more than 1.1 mg\u002FdL or a doubling of the serum creatinine concentration in the absence of other renal disease)\n* Pulmonary edema\n* New-onset headache unresponsive to medication and not accounted for by alternative diagnoses\n* Visual disturbances\n* Underlying renal dysfunction defined as, presenting the following parameters prior to 20 weeks gestation: baseline creatinine, equal to or higher than, 1.2 mg\u002FdL Or proteinuria: defined as presenting protein in urine, equal to or higher than, 300 mg\u002F24 hours or protein\u002Fcreatinine ratio, equal to or higher than, 0.3 or Urine dipstick reading of greater than or equal to 2 at baseline and in the absence of a urinary tract infection\n* Stage 2 chronic hypertension\n* Contraindications to labetalol and nifedipine XL according to the FDA package insert\n* Patient unable to or unwilling to adhere to management recommendations\n* Fetal Reasons for Study Ineligibility:\n* Fetal growth restriction (lower than 10th percentile) at enrollment, based on an ultrasound within 3 weeks prior to enrollment\n* Oligohydramnios defined by amniotic fluid deepest vertical pocket \\\u003C2 cm based on an ultrasound within the 48 hours prior to enrollment\n* Known major structural or chromosomal abnormality","14 Years","49 Years",{"count":277,"type":21},132,[24],"The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140\u002F90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.",[97,66,28],"2025-12-08",{"date":283,"type":41},"2025-12-12",{"date":285,"type":41},"2023-02-14",{"date":287,"type":21},"2027-06",{"name":289,"class":48},"University of Alabama at Birmingham",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":300,"conditions":301,"keywords":303,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":4},"100610074","phase-3-cardiovascular-protection-after-preeclampsia-with-enalapril-100610074","NCT07222852","Cardiovascular Protection After Preeclampsia With Enalapril","CAPP-E","Inclusion Criteria:\n\n* Postpartum individuals\n* ≥18 years old\n* Hypertensive disorder of pregnancy\n* Enrolled in Women and Infants Hospital Hypertension Equity remote monitoring program.\n\nExclusion Criteria:\n\n* Maternal cardiac disease\n* Individuals with pre-pregnancy hypertension or diabetes\n* Allergy or contraindication to enalapril",{"count":58,"type":21},[299],"PHASE3","The purpose of this study is to learn if postpartum women are willing to be randomized to different blood pressure medicines after delivery and how that affects blood pressure in women with hypertensive disorders of pregnancy.",[97,28,64,66,302],"Gestational Hypertension After Childbirth",[304],"postpartum hypertension, preeclampsia, gestational hypertension","2025-10-29",{"date":307,"type":41},"2025-10-30",{"date":309,"type":21},"2025-11-15",{"date":311,"type":21},"2027-10-15",{"name":313,"class":48},"Women and Infants Hospital of Rhode Island",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":91,"sex":321,"minAge":4,"maxAge":4,"enrollmentInfo":322,"targetDuration":324,"studyType":118,"phases":4,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":83},"100524929","peppi-study-identification-of-women-at-risk-for-placental-dysfunction-100524929","NCT06115122","PEPPI Study: Identification of Women at Risk for Placental Dysfunction","PEPPI Study: Identification of Women at Risk for Placental Dysfunction During the First and Third Trimesters of Pregnancy","Mothers\n\nInclusion Criteria for PEPPI-study\n\n* Pregnant (first trimester)\n* Understands Finnish\n* ≥18 years\n* Signed informed consent\n\nExclusion Criteria\n\n* Multiple pregnancy\n* Miscarriage\u002Ftermination of the index pregnancy\n* No first trimester blood sampling\n\nInclusion Criteria for FERPPI-study\n\n* Participates in PEPPI-study (criteria above)\n* Blood samples at first and third trimester of pregnancy\n* Permits blood sampling from the umbilical cord when the baby is born\n\nExclusion Criteria\n\n* No first or third trimester blood sampling\n* No umbilical cord blood sample after baby is born\n\nFathers\n\nInclusion Criteria\n\n* Biological father to the child born for the mother who participated in PEPPI study\n* ≥18 years\n* Signed informed consent\n\nExclusion Criteria\n\n• Does not understand Finnish\n\nChildren\n\nInclusion Criteria for PEPPI-study\n\n* Born to mother who participated in PEPPI study\n* Signed informed consent from parent(s)\n\nExclusion Criteria\n\n• No consent from parent(s)\n\nInclusion Criteria for PEPPI-offspring study • Mother in risk-, control-, or PCOS group during PEPPI-study with ultrasound information at gestational weeks 30-32 or a mother who developed pre-eclampsia during the pregnancy regardless of their study group during PEPPI-study\n\nExclusion Criteria\n\n• Mother\u002Ffather declines participation\n\nInclusion Criteria for FERPPI-study\n\n* Signed informed consent from parent(s)\n* Mother has blood samples taken at first and third trimester (iron status)\n* Child has blood samples taken at birth and at 3 months of age\n\nExclusion Criteria\n\n* No consent from parent(s)\n* No blood samples from mother\n* No blood samples from child","ALL",{"count":323,"type":21},3000,"15 Years","The main purpose of this study is to evaluate Fetal Medicine Foundation's pre-eclampsia risk calculator using maternal characteristics, first trimester serum placental growth factor (PlGF) and mean arterial pressure (MAP) in a Finnish general population.\n\nCondition or disease: pre-eclampsia, intrauterine growth restriction, polycystic ovary syndrome",[63,122,327,328,67,28,329],"Polycystic Ovary Syndrome","Iron-deficiency","Proteinuria in Pregnancy","2025-07-31",{"date":332,"type":41},"2025-08-05",{"date":334,"type":41},"2022-02-15",{"date":336,"type":21},"2041-12-31",{"name":338,"class":48},"Oulu University Hospital",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":91,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":349,"conditions":350,"keywords":351,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":358,"leadSponsor":360,"locationsCount":83},"100586215","endothelial-dysfunction-for-prognosis-in-patients-with-preeclampsia-100586215","NCT06912477","Endothelial Dysfunction for Prognosis In Patients With preeClampSia","Systematic Evaluation of Endothelial Dysfunction as a Prognostic Marker for Outcomes in Women With Preeclampsia","EPICS","Inclusion Criteria:\n\n* singleton pregnancies\n* Age ≥ 18 years\n* Patient's ability to provide consent\n* written informed consent\n\nExclusion Criteria:\n\n* Lack of consent\n* Language barrier\n* Dark to very dark skin type\n* Severe fetal chromosomal\u002Fgenetic\u002Fstructural anomalies\n* Laboratory changes in LDH, creatinine, or platelets due to other causes (e.g., isolated thrombocytopenia, e.g., immune thrombocytopenia, carcinoma)",{"count":348,"type":21},385,"Preeclampsia is a pregnancy-specific hypertensive disorder and can progress rapidly to severe adverse outcomes affecting both the mother and the fetus. Endothelial and microcirculatory dysfunction mediate systemic preeclampsia-related organ dysfunctions. Changes in endothelial and vascular function in preeclampsia have been demonstrated through reduced flow-mediated vasodilation as a result of reduced availability of nitric oxide, which potentially persists up to several years postpartum. Hyperspectral imaging is a new innovative technology that allows to assess the peripheral microcirculation and perfusion non-invasively and contactless, but has never been evaluated in the context of preeclampsia before.\n\nThis EPICS project (Endothelial dysfunction for Prognosis In patients with preeClampSia) is a prospective observational study and aims to investigate hyperspectral imaging as a new potential diagnostic and prognostic marker in preeclampsia.",[253,28],[255,352,353],"hyperspectral imaging","endothelial dysfunction","2025-05-08",{"date":356,"type":41},"2025-05-11",{"date":354,"type":41},{"date":359,"type":21},"2027-07",{"name":361,"class":48},"Heidelberg University",{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":17,"minAge":370,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":83},"100553831","home-assessment-of-blood-pressure-in-pregnancy-100553831","NCT06491199","Home Assessment of Blood Pressure in PregnancY","HABPY: Home Assessment of Blood Pressure in PregnancY","HABPY","Inclusion Criteria:\n\n* Adult patients aged ≥ 19 years\n* Pregnancy\n* Gestational age 20+0 to 36+0 weeks gestational age\n* Diagnosed with gestational hypertension (defined as SBP ≥140 mm Hg and\u002For DBP ≥ 90 mm Hg) after 20 weeks gestation OR Chronic hypertension (defined as SBP ≥140 mm Hg and\u002For DBP ≥ 90 mm Hg), present at booking or before 20 weeks gestation, or receiving treatment (including lifestyle measures) prior to pregnancy and\u002For at time of referral OR Transient elevated office BP reading (defined as one time reading of SBP ≥140 mm Hg and\u002For DBP ≥ 90 mm Hg with risk factors for HDP as per Canadian guidelines).\n* Participant is willing and able to give informed consent for participation in the study\n* Able and willing to comply with study requirements\n* Has smart phone\n\nExclusion Criteria:\n\n* Anticipated inpatient admission\n* Remaining pregnancy less than 2 weeks duration\n* Imminent delivery (within the next 48 hours)\n* Non-English speaking or no family members who can help translate","19 Years",{"count":372,"type":21},100,"The goal of this observational study is to evaluate the feasibility and safety of a comprehensive home blood pressure telemonitoring (HBPT) program for pregnant people with hypertensive disorders of pregnancy (HDP).\n\nParticipants will receive training on the use of a home BP telemonitor with tele-transmission function for the remainder of their pregnancy and 6 weeks postpartum. Participating obstetric internal medicine (OBIM) clinicians will monitor the transmitted values and adjust anti-hypertensive medications based on the home BP readings.\n\nOur primary goal is to describe the feasibility and safety of a comprehensive HBPT pilot program in British Columbia, Canada (BC).\n\nSecondary research questions will address:\n\n1. What is the end-user acceptability of a comprehensive HBPT pilot program in BC?\n2. What are the effects of a comprehensive HBPT pilot program on factors such as:\n\n1\\. Maternal and neonatal outcomes 2. Home blood pressure (BP) metrics 3. Process measures 4. Anti-hypertensive medications 5. Fidelity to interventions 6. Health Care utilization",[28],"2024-06-29",{"date":377,"type":41},"2024-07-09",{"date":379,"type":21},"2024-07",{"date":381,"type":21},"2026-01",{"name":383,"class":48},"University of British Columbia",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":91,"sex":321,"minAge":391,"maxAge":4,"enrollmentInfo":392,"targetDuration":394,"studyType":118,"phases":4,"briefSummary":395,"conditions":396,"keywords":398,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":83},"100545129","the-preeclampsia-registry-100545129","NCT06377878","The Preeclampsia Registry","TPR","Inclusion Criteria:\n\n* Women who were medically diagnosed with preeclampsia or a related hypertensive disorder of pregnancy (HDP) such as eclampsia or HELLP syndrome.\n* Female or Male relatives of affected women\n* Women who have never had preeclampsia or hypertensive disorders of pregnancy, but who would like to serve as \"controls\" in research studies of preeclampsia.\n* An authorized representative may complete the questionnaire and provide consent for a woman who had preeclampsia, but has died or is disabled as a result.\n\nExclusion Criteria:\n\n* Those unable to provide consent\n* Prisoners\n* Individuals unable to speak English","13 Years",{"count":393,"type":21},20000,"20 Years","The purpose of The Preeclampsia Registry is to collect and store medical and other information from women who have been medically diagnosed with preeclampsia or a related hypertensive (high blood pressure) disorder of pregnancy such as eclampsia or HELLP syndrome, their family members, and women who have not had preeclampsia to serve as controls. Information from participants will be used for medical research to try to understand why preeclampsia occurs, how to predict it better, and to develop experimental clinical trials of new treatments. The Registry will consist of a web-based survey and mechanism for collecting and reviewing medical records. This data will be utilized for immediate investigator-driven cross-sectional research projects (after proposal review by the Registry's scientific advisory board and as directed by the PI). Participants may also choose to be contacted regarding possible participation in future studies, about providing a biospecimen, as well as investigator-driven clinical trials. The Registry is anticipated to exist long-term and to serve as a foundation of participants from which to draw for studies of preeclampsia, anticipated to evolve as our scientific understanding of preeclampsia evolves.",[97,65,397,68,28],"HELLP Syndrome",[97,65,399,397,68,28,400,401,145,402,403,404,64],"HELLP","Registry","Pregnancy Complication","Maternal Death","Premature","High Blood Pressure","2024-04-17",{"date":407,"type":41},"2024-04-22",{"date":409,"type":41},"2013-09-01",{"date":411,"type":21},"2040-05",{"name":413,"class":48},"Preeclampsia Foundation",{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":22,"phases":423,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":432,"locationsCount":83},"100515715","mhealth-for-hypertensive-disorder-of-pregnancy-100515715","NCT05995106","mHealth for Hypertensive Disorder of Pregnancy","Prospective Validation of Usefulness in the Hypertensive Disorder of Pregnancy With Cardiovascular Disease Management Solution Based on Interconnection to Hospital Examination","Inclusion Criteria:\n\n* Diagnosis: 1 or 2\n\n  1. Pregnant women diagnosed with hypertensive disorders of pregnancy at or beyond 12 weeks of gestation:\n\n     * Chronic hypertension: Diagnosed with hypertension within 20 weeks of gestation (elevated office\u002Fclinic blood pressure ≥140\u002F90 mm Hg) or currently on antihypertensive medication.\n     * Gestational hypertension: Newly diagnosed with hypertension after 20 weeks of gestation (elevated office\u002Fclinic blood pressure ≥140\u002F90 mm Hg) or currently on antihypertensive medication.\n     * Preeclampsia: Newly diagnosed with hypertension after 20 weeks of gestation (elevated office\u002Fclinic blood pressure ≥140\u002F90 mm Hg) or currently on antihypertensive medication, and presents with proteinuria (300 mg\u002F24 hours or urine protein-to-creatinine ratio ≥0.3), thrombocytopenia (less than 100,000 platelets per microliter), abnormal renal function (creatinine exceeding 1.1 or doubling of baseline), elevated liver enzymes (twice normal levels), neurological symptoms (headache, visual disturbances, seizures, etc.), and\u002For pulmonary edema.\n     * Superimposed preeclampsia: Diagnosed with hypertension within 20 weeks of gestation (elevated office\u002Fclinic blood pressure ≥140\u002F90 mm Hg) or currently on antihypertensive medication and experiences symptoms or signs related to superimposed preeclampsia.\n  2. Pregnant women at elevated risk for hypertensive disorders of pregnancy:\n\n     Multifetal gestation, obesity, uncontrolled gestational or pre-existing diabetes, history of hypertensive disorder of pregnancy leading to preterm birth, presence of borderline blood pressure readings during antepartum care (elevated office\u002Fclinic blood pressure ≥130\u002F80 mm Hg) following a previous diagnosis of hypertension-related disorder in a prior pregnancy.\n\n     , and\n* Adult individuals aged 18 years and above who possess a smartphone and are capable of independently utilizing the application among pregnant women.\n\nExclusion Criteria:\n\n* Patients with evidence of delusions, confusion, or other cognitive disorders.\n* Patients deemed difficult to conduct this study on by the researchers due to various reasons.\n* Cases where device familiarity is significantly low, making data collection challenging.\n* Pregnant patients requiring immediate electronic fetal monitoring or maternal monitoring due to imminent delivery.",{"count":422,"type":21},580,[24],"Objectives: We have developed a cardiovascular disease management application named Heart4U, with the capability of integrating with the Electronic Medical Records (EMR) system within the hospital.\n\nThe main goal of this study is to evaluate the clinical effectiveness of a treatment approach that entails self-management of risk factors through a mobile application among pregnant individuals diagnosed with hypertensive cardiovascular conditions.\n\nMethods: Patients assigned to the app group receive assistance from the research team to install the Heart4U application and familiarize themselves with its usage. Both the app group and the usual care group continue to receive active treatment as previously administered (guideline-based prenatal care). Follow-up observations occur at each obstetric examination prior to delivery and are conducted again at the first month postpartum. The primary endpoint of observation pertains to the difference in systolic blood pressure between the enrollment and study completion time points.",[28,97],"2023-12-15",{"date":428,"type":41},"2023-12-21",{"date":430,"type":41},"2023-10-02",{"date":287,"type":21},{"name":433,"class":48},"Seoul National University Hospital"]